inter-alpha-trypsin inhibitor heavy chain 3Genealiases: H3P · ITI-HC3 · SHAP
Q-omics provides the consensus-scored ITIH3 profile across patient tissues and cancer cell-line models. ITIH3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ITIH3 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, ITIH3 RNA expression shows 23,341 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, and LUAD as cancer lineages where ITIH3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ITIH3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ITIH3 survival associations across molecular data types. ITIH3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ITIH3 RNA expression–survival associations across cancer types. High ITIH3 expression shows unfavorable associations in ACC, KIRP, LUSC, STAD and KIRC, but favorable associations in UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ITIH3 RNA expression.
This table summarizes ITIH3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ITIH3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ITIH3 shows lower tumor expression in LUAD, THCA, LUSC, UCEC, BRCA and BLCA. The LUAD box plot shows higher ITIH3 RNA expression in normal versus tumor tissue (log2 FC = −1.210, t-test p < 0.001).
This table shows molecular features associated with ITIH3 in patient tissues and cancer cell lines. In patient samples, ITIH3 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ITIH3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
